Phenylketonuria Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global Phenylketonuria (PKU) treatment market is on the brink of substantial growth, forecasted to expand significantly over the next decade. This growth is fueled by a rising demand for treatment solutions and breakthrough advancements in treatment methodologies. As of 2024, the market is valued at approximately $1.28 billion, and it is projected to reach around $2.31 billion by 2031. This expansion represents a steady Compound Annual Growth Rate (CAGR) of 8.8%, indicating robust market dynamics and increasing investment in PKU treatments.

Market Overview

Fairfield Market Research highlights that finished products, including essential and non-essential amino acids, currently dominate the market, making up a significant portion of the market share. These products represent a considerable segment of the global amino acid market.

Historical Growth and Future Outlook

The phenylketonuria treatment market has witnessed a CAGR of over 7% in recent years. The increasing prevalence of PKU among newborns has fueled the demand for effective treatments. Early newborn screening has played a crucial role in identifying the condition, which is critical for managing it effectively.

Research on PKU treatment has expanded, particularly in the development of the PKU diet and PKU formula, which are essential components of treatment. Innovations in adjuvant therapies have shown potential in helping patients achieve therapeutic goals and possibly modifying their diets to include more varied foods.

Innovations and Clinical Research

Recent clinical studies, including randomized controlled trials (RCTs) and open-label trials, have shown that Tetrahydrobiopterin (BH4) can reduce phenylalanine levels in some patients. Such advancements are crucial as PKU, if untreated, can lead to significant intellectual impairment.

Global Market Dynamics

The prevalence of PKU is on the rise globally, affecting both adults and newborns. Countries like the United States, Ireland, and Turkey show varying prevalence rates, influencing the demand for treatments. Manufacturers are responding to this demand by focusing on the development of more effective PKU formulations and exploring novel therapeutic avenues.

Growth Opportunities

The market is witnessing strategic mergers and acquisitions, highlighting a trend towards consolidation. This strategy is prevalent across North America, Latin America, Europe, Asia-Pacific, the Middle East, and Africa. For instance, notable collaborations in the industry are expected to yield significant returns, enhancing the production and distribution of innovative PKU treatments.

Challenges to Market Growth

Adherence to the strict PKU diet, which is low in phenylalanine, remains a challenge. This diet restricts natural protein sources like cereal and pasta, which can disrupt metabolic control. High treatment costs and varied reimbursement policies across countries also pose significant barriers to market growth.

Country-wise Insights

United States: The U.S. leads in market share and research efforts, thanks to a high prevalence of PKU and substantial government funding for research.
Germany: Known for its high PKU prevalence, Germany offers promising market opportunities, highlighted by the launch of innovative products like PKU GOLIKE(R).
Australia: The demand for amino acid products is rising, along with growing activities by contract research organizations (CROs), making Australia a key player in the market.

Competitive Analysis

Digital promotion and e-commerce are vital strategies for reaching the target market. Major players in the market are focusing on enhancing their product portfolios and promoting their offerings at major global platforms and conferences. Some of the key players include Danone S.A. (Nutricia), APR Applied Pharma Research S.A., and Arla Foods Ingredients Group P/S, among others.

Market Segmentation

Amino acids play a critical role in managing PKU, with essential and non-essential amino acids driving demand within the market. Granular forms of these products are preferred for their better bioavailability and stability compared to powders.

Adults represent a significant customer base for PKU treatments, especially with treatments like Palynziq(R) gaining FDA approval for adult use. Retail pharmacies are pivotal in making these treatments accessible, offering both branded and generic formulations.

PKU Ingredients:

Protein Ingredient
- Essential and non-essential amino acids
- Glycomacropeptide (GMP)
Finish Product
- Essential and non-essential amino acids
- Glycomacropeptide (GMP)

Form:

Protein Ingredient
- Powder Blend
- Granules
Finish Product
- Powder & Granules
- Tablet & Capsules
- Powder Sachets
- Ready-to-Drink
- Shake
- Others

Targeted Customer:

Protein Ingredient
- Consumer Healthcare Companies
- Pharmaceutical Companies
- Contract Manufacturing Companies (CMOs)
Finish Product
- Adults
- Paediatrics
- Pregnant Women

Sales Channel:

Protein Ingredient
- Industry Sales (Ingredients)
Finish Product
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Hypermarkets & Supermarkets

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Phenylketonuria Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Phenylketonuria Treatment Market Outlook, 2018 - 2031

3.1. Global Phenylketonuria Treatment Market Outlook, by PKU Ingredients, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Protein Ingredient
    - 3.1.1.1.1. Essential and non-essential amino acids
    - 3.1.1.1.2. Glycomacropeptide (GMP)
  - 3.1.1.2. Finish Product
    - 3.1.1.2.1. Essential and non-essential amino acids
    - 3.1.1.2.2. Glycomacropeptide (GMP)
3.2. Global Phenylketonuria Treatment Market Outlook, by Form, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Protein Ingredient
    - 3.2.1.1.1. Powder Blend
    - 3.2.1.1.2. Granules
  - 3.2.1.2. Finish Product
    - 3.2.1.2.1. Powder & Granules
    - 3.2.1.2.2. Tablet & Capsules
    - 3.2.1.2.3. Powder Sachets
    - 3.2.1.2.4. Ready-to-Drink
    - 3.2.1.2.5. Shake
    - 3.2.1.2.6. Others
3.3. Global Phenylketonuria Treatment Market Outlook, by Targeted Customer, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Protein Ingredient
    - 3.3.1.1.1. Consumer Healthcare Companies
    - 3.3.1.1.2. Pharmaceutical Companies
    - 3.3.1.1.3. Contract Manufacturing Companies (CMOs)
  - 3.3.1.2. Finish Product
    - 3.3.1.2.1. Adults
    - 3.3.1.2.2. Paediatrics
    - 3.3.1.2.3. Pregnant Women
3.4. Global Phenylketonuria Treatment Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Protein Ingredient
    - 3.4.1.1.1. Industry Sales (Ingredients)
  - 3.4.1.2. Finish Product
    - 3.4.1.2.1. Hospital Pharmacies
    - 3.4.1.2.2. Retail Pharmacies
    - 3.4.1.2.3. Online Pharmacies
    - 3.4.1.2.4. Hypermarkets & Supermarkets
3.5. Global Phenylketonuria Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Phenylketonuria Treatment Market Outlook, 2018 - 2031

4.1. Global Phenylketonuria Treatment Market Outlook, by PKU Ingredients, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Protein Ingredient
    - 4.1.1.1.1. Essential and non-essential amino acids
    - 4.1.1.1.2. Glycomacropeptide (GMP)
  - 4.1.1.2. Finish Product
    - 4.1.1.2.1. Essential and non-essential amino acids
    - 4.1.1.2.2. Glycomacropeptide (GMP)
4.2. North America Phenylketonuria Treatment Market Outlook, by Form, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Protein Ingredient
    - 4.2.1.1.1. Powder Blend
    - 4.2.1.1.2. Granules
  - 4.2.1.2. Finish Product
    - 4.2.1.2.1. Powder & Granules
    - 4.2.1.2.2. Tablet & Capsules
    - 4.2.1.2.3. Powder Sachets
    - 4.2.1.2.4. Ready-to-Drink
    - 4.2.1.2.5. Shake
    - 4.2.1.2.6. Others
4.3. North America Phenylketonuria Treatment Market Outlook, by Targeted Customer, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Protein Ingredient
    - 4.3.1.1.1. Consumer Healthcare Companies
    - 4.3.1.1.2. Pharmaceutical Companies
    - 4.3.1.1.3. Contract Manufacturing Companies (CMOs)
  - 4.3.1.2. Finish Product
    - 4.3.1.2.1. Adults
    - 4.3.1.2.2. Paediatrics
    - 4.3.1.2.3. Pregnant Women
4.4. North America Phenylketonuria Treatment Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Protein Ingredient
    - 4.4.1.1.1. Industry Sales (Ingredients)
  - 4.4.1.2. Finish Product
    - 4.4.1.2.1. Hospital Pharmacies
    - 4.4.1.2.2. Retail Pharmacies
    - 4.4.1.2.3. Online Pharmacies
    - 4.4.1.2.4. Hypermarkets & Supermarkets
4.5. North America Phenylketonuria Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 4.5.1.2. U.S. Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 4.5.1.3. U.S. Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 4.5.1.4. U.S. Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 4.5.1.5. Canada Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 4.5.1.6. Canada Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 4.5.1.7. Canada Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 4.5.1.8. Canada Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Phenylketonuria Treatment Market Outlook, 2018 - 2031

5.1. Europe Phenylketonuria Treatment Market Outlook, by PKU Ingredients, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Protein Ingredient
    - 5.1.1.1.1. Essential and non-essential amino acids
    - 5.1.1.1.2. Glycomacropeptide (GMP)
  - 5.1.1.2. Finish Product
    - 5.1.1.2.1. Essential and non-essential amino acids
    - 5.1.1.2.2. Glycomacropeptide (GMP)
5.2. Europe Phenylketonuria Treatment Market Outlook, by Form, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Protein Ingredient
    - 5.2.1.1.1. Powder Blend
    - 5.2.1.1.2. Granules
  - 5.2.1.2. Finish Product
    - 5.2.1.2.1. Powder & Granules
    - 5.2.1.2.2. Tablet & Capsules
    - 5.2.1.2.3. Powder Sachets
    - 5.2.1.2.4. Ready-to-Drink
    - 5.2.1.2.5. Shake
    - 5.2.1.2.6. Others
5.3. Europe Phenylketonuria Treatment Market Outlook, by Targeted Customer, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Protein Ingredient
    - 5.3.1.1.1. Consumer Healthcare Companies
    - 5.3.1.1.2. Pharmaceutical Companies
    - 5.3.1.1.3. Contract Manufacturing Companies (CMOs)
  - 5.3.1.2. Finish Product
    - 5.3.1.2.1. Adults
    - 5.3.1.2.2. Paediatrics
    - 5.3.1.2.3. Pregnant Women
5.4. Europe Phenylketonuria Treatment Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Protein Ingredient
    - 5.4.1.1.1. Industry Sales (Ingredients)
  - 5.4.1.2. Finish Product
    - 5.4.1.2.1. Hospital Pharmacies
    - 5.4.1.2.2. Retail Pharmacies
    - 5.4.1.2.3. Online Pharmacies
    - 5.4.1.2.4. Hypermarkets & Supermarkets
5.5. Europe Phenylketonuria Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 5.5.1.2. Germany Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 5.5.1.3. Germany Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 5.5.1.4. Germany Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.5. U.K. Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 5.5.1.6. U.K. Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 5.5.1.7. U.K. Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 5.5.1.8. U.K. Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.9. France Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 5.5.1.10. France Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 5.5.1.11. France Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 5.5.1.12. France Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.13. Italy Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 5.5.1.14. Italy Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 5.5.1.15. Italy Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 5.5.1.16. Italy Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.17. Turkey Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 5.5.1.18. Turkey Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 5.5.1.19. Turkey Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 5.5.1.20. Turkey Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.21. Russia Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 5.5.1.22. Russia Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 5.5.1.23. Russia Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 5.5.1.24. Russia Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.25. Rest of Europe Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 5.5.1.26. Rest of Europe Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 5.5.1.27. Rest of Europe Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 5.5.1.28. Rest of Europe Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Phenylketonuria Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Phenylketonuria Treatment Market Outlook, by PKU Ingredients, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Protein Ingredient
    - 6.1.1.1.1. Essential and non-essential amino acids
    - 6.1.1.1.2. Glycomacropeptide (GMP)
  - 6.1.1.2. Finish Product
    - 6.1.1.2.1. Essential and non-essential amino acids
    - 6.1.1.2.2. Glycomacropeptide (GMP)
6.2. Asia Pacific Phenylketonuria Treatment Market Outlook, by Form, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Protein Ingredient
    - 6.2.1.1.1. Powder Blend
    - 6.2.1.1.2. Granules
  - 6.2.1.2. Finish Product
    - 6.2.1.2.1. Powder & Granules
    - 6.2.1.2.2. Tablet & Capsules
    - 6.2.1.2.3. Powder Sachets
    - 6.2.1.2.4. Ready-to-Drink
    - 6.2.1.2.5. Shake
    - 6.2.1.2.6. Others
6.3. Asia Pacific Phenylketonuria Treatment Market Outlook, by Targeted Customer, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Protein Ingredient
    - 6.3.1.1.1. Consumer Healthcare Companies
    - 6.3.1.1.2. Pharmaceutical Companies
    - 6.3.1.1.3. Contract Manufacturing Companies (CMOs)
  - 6.3.1.2. Finish Product
    - 6.3.1.2.1. Adults
    - 6.3.1.2.2. Paediatrics
    - 6.3.1.2.3. Pregnant Women
6.4. Asia Pacific Phenylketonuria Treatment Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Protein Ingredient
    - 6.4.1.1.1. Industry Sales (Ingredients)
  - 6.4.1.2. Finish Product
    - 6.4.1.2.1. Hospital Pharmacies
    - 6.4.1.2.2. Retail Pharmacies
    - 6.4.1.2.3. Online Pharmacies
    - 6.4.1.2.4. Hypermarkets & Supermarkets
6.5. Asia Pacific Phenylketonuria Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. China Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 6.5.1.2. China Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 6.5.1.3. China Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 6.5.1.4. China Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.5. Japan Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 6.5.1.6. Japan Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 6.5.1.7. Japan Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 6.5.1.8. Japan Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.9. South Korea Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 6.5.1.10. South Korea Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 6.5.1.11. South Korea Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 6.5.1.12. South Korea Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.13. India Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 6.5.1.14. India Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 6.5.1.15. India Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 6.5.1.16. India Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.17. Southeast Asia Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 6.5.1.18. Southeast Asia Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 6.5.1.19. Southeast Asia Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 6.5.1.20. Southeast Asia Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.21. Rest of Asia Pacific Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 6.5.1.22. Rest of Asia Pacific Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 6.5.1.23. Rest of Asia Pacific Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 6.5.1.24. Rest of Asia Pacific Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Phenylketonuria Treatment Market Outlook, 2018 - 2031

7.1. Latin America Phenylketonuria Treatment Market Outlook, by PKU Ingredients, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Protein Ingredient
    - 7.1.1.1.1. Essential and non-essential amino acids
    - 7.1.1.1.2. Glycomacropeptide (GMP)
  - 7.1.1.2. Finish Product
    - 7.1.1.2.1. Essential and non-essential amino acids
    - 7.1.1.2.2. Glycomacropeptide (GMP)
7.2. Latin America Phenylketonuria Treatment Market Outlook, by Form, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Protein Ingredient
    - 7.2.1.1.1. Powder Blend
    - 7.2.1.1.2. Granules
  - 7.2.1.2. Finish Product
    - 7.2.1.2.1. Powder & Granules
    - 7.2.1.2.2. Tablet & Capsules
    - 7.2.1.2.3. Powder Sachets
    - 7.2.1.2.4. Ready-to-Drink
    - 7.2.1.2.5. Shake
    - 7.2.1.2.6. Others
7.3. Latin America Phenylketonuria Treatment Market Outlook, by Targeted Customer, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Protein Ingredient
    - 7.3.1.1.1. Consumer Healthcare Companies
    - 7.3.1.1.2. Pharmaceutical Companies
    - 7.3.1.1.3. Contract Manufacturing Companies (CMOs)
  - 7.3.1.2. Finish Product
    - 7.3.1.2.1. Adults
    - 7.3.1.2.2. Paediatrics
    - 7.3.1.2.3. Pregnant Women
7.4. Latin America Phenylketonuria Treatment Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Protein Ingredient
    - 7.4.1.1.1. Industry Sales (Ingredients)
  - 7.4.1.2. Finish Product
    - 7.4.1.2.1. Hospital Pharmacies
    - 7.4.1.2.2. Retail Pharmacies
    - 7.4.1.2.3. Online Pharmacies
    - 7.4.1.2.4. Hypermarkets & Supermarkets
7.5. Latin America Phenylketonuria Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 7.5.1.2. Brazil Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 7.5.1.3. Brazil Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 7.5.1.4. Brazil Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 7.5.1.5. Mexico Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 7.5.1.6. Mexico Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 7.5.1.7. Mexico Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 7.5.1.8. Mexico Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 7.5.1.9. Argentina Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 7.5.1.10. Argentina Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 7.5.1.11. Argentina Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 7.5.1.12. Argentina Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 7.5.1.13. Rest of Latin America Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 7.5.1.14. Rest of Latin America Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 7.5.1.15. Rest of Latin America Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 7.5.1.16. Rest of Latin America Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Phenylketonuria Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Phenylketonuria Treatment Market Outlook, by PKU Ingredients, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Protein Ingredient
    - 8.1.1.1.1. Essential and non-essential amino acids
    - 8.1.1.1.2. Glycomacropeptide (GMP)
  - 8.1.1.2. Finish Product
    - 8.1.1.2.1. Essential and non-essential amino acids
    - 8.1.1.2.2. Glycomacropeptide (GMP)
8.2. Middle East & Africa Phenylketonuria Treatment Market Outlook, by Form, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Protein Ingredient
    - 8.2.1.1.1. Powder Blend
    - 8.2.1.1.2. Granules
  - 8.2.1.2. Finish Product
    - 8.2.1.2.1. Powder & Granules
    - 8.2.1.2.2. Tablet & Capsules
    - 8.2.1.2.3. Powder Sachets
    - 8.2.1.2.4. Ready-to-Drink
    - 8.2.1.2.5. Shake
    - 8.2.1.2.6. Others
8.3. Middle East & Africa Phenylketonuria Treatment Market Outlook, by Targeted Customer, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Protein Ingredient
    - 8.3.1.1.1. Consumer Healthcare Companies
    - 8.3.1.1.2. Pharmaceutical Companies
    - 8.3.1.1.3. Contract Manufacturing Companies (CMOs)
  - 8.3.1.2. Finish Product
    - 8.3.1.2.1. Adults
    - 8.3.1.2.2. Paediatrics
    - 8.3.1.2.3. Pregnant Women
8.4. Middle East & Africa Phenylketonuria Treatment Market Outlook, by Sales Channel, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Protein Ingredient
    - 8.4.1.1.1. Industry Sales (Ingredients)
  - 8.4.1.2. Finish Product
    - 8.4.1.2.1. Hospital Pharmacies
    - 8.4.1.2.2. Retail Pharmacies
    - 8.4.1.2.3. Online Pharmacies
    - 8.4.1.2.4. Hypermarkets & Supermarkets
8.5. Middle East & Africa Phenylketonuria Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 8.5.1.2. GCC Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 8.5.1.3. GCC Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 8.5.1.4. GCC Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 8.5.1.5. South Africa Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 8.5.1.6. South Africa Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 8.5.1.7. South Africa Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 8.5.1.8. South Africa Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 8.5.1.9. Egypt Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 8.5.1.10. Egypt Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 8.5.1.11. Egypt Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 8.5.1.12. Egypt Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 8.5.1.13. Nigeria Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 8.5.1.14. Nigeria Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 8.5.1.15. Nigeria Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 8.5.1.16. Nigeria Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
  - 8.5.1.17. Rest of Middle East & Africa Phenylketonuria Treatment Market by PKU Ingredients, Value (US$ Bn), 2018 - 2031
  - 8.5.1.18. Rest of Middle East & Africa Phenylketonuria Treatment Market by Form, Value (US$ Bn), 2018 - 2031
  - 8.5.1.19. Rest of Middle East & Africa Phenylketonuria Treatment Market by Targeted Customer, Value (US$ Bn), 2018 - 2031
  - 8.5.1.20. Rest of Middle East & Africa Phenylketonuria Treatment Market by Sales Channel, Value (US$ Bn), 2018 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Targeted Customer vs By Form Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Arla Foods Ingredients Group P/S
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Archer Daniels Midland Company
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. BASF SE
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Chr. Hansen
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Cargill, Incorporated
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Seidler Chemical Co, Inc.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Nestle S.A. (Vitaflo International)
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Reckitt Benckiser Group plc. (Mead Johnson & Company, LLC.)
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Abbott Laboratories
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. APR Applied Pharma Research S. A.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Ajinomoto Co., Inc.
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Vitafriends PKU
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. Pristine Organics Pvt. Ltd
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Product Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations